Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy)

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 1, 1996, Pages 119-122

  Yousfi, M M ^a   El Zimaity, H M T ^a   Cole, R A ^a   Genta, R M ^a   Graham, D Y ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; METRONIDAZOLE; RANITIDINE;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; FEMALE; HELICOBACTER PYLORI; HUMAN; MALE; PEPTIC ULCER; PRIORITY JOURNAL; TASTE DISORDER;

EID: 0030032679     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.1996.tb00185.x     Document Type: Article

References (26)

1. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994; 272: 65-9.
2. Peura DA, Graham DY. Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic disease. Am J Gastroenterol 1994; 89: 1137-9.
3. Bank S, Chow K, Greenburg R. Helicobacter pylori and recurrence of duodenal ulcers. Am J Gastroenterol 1992; 87: 1365-7.
4. Tytgat GNJ, Lee A, Graham DY, Dixon MF, Rokkas T. The role of infectious agents in peptic ulcer disease. Gastroenterol Int 1993; 6: 76-89.
5. Graham DY. Benefits from elimination of Helicobacter pylori infection include major reduction in the incidence of peptic ulcer disease, gastric cancer, and primary gastric lymphoma. Preventive Med 1994; 23: 712-6.
6. Fennerty MB. Helicobacter pylori. Arch Intern Med 1994; 154: 721-7.
7. Marshall BJ. Helicobacter pylori. Am J Gastroenterol 1994; 89: S116-27.
8. Rune SJ. Treatment strategies for symptom resolution, healing, and Helicobacter pylori eradication in duodenal ulcer patients. Scand J Gastroenterol 1994; 29 (Suppl 205): 45-7.
9. Glupczynski Y, Burette A. Drug therapy for Helicobacter pylori infection: problems and pitfalls. Am J Gastroenterol 1990; 85: 1545-51.
10. Börsch GM, Graham DY. Helicobacter pylori. In : Collen MJ, Benjamin SB, eds. Pharmacology of Peptic Ulcer Disease. Handbook of Experimental Pharmacology, Vol 99. Berlin: Springer, 1991: 107-48.
11. Glupczynski Y, Burette A, De Koster E, et al. Metronidazole resistance in Helicobacter pylori. (Letter.) Lancet 1990; 335: 976-7.
12. O'Riordan TG, Mathai E, Tobin E, et al. Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate. Gut 1990; 31: 999-1002.
13. Weil J, Bell GD, Powell K, et al. Helicobacter pylori and metronidazole resistance. (Letter.) Lancet 1990; 336: 1445.
14. Becx MC, Janssen AJ, Clasener HA, de Koning RW. Metronidazole-resistant Helicobacter pylori, (letter.) Lancet 1990; 335: 539-10.
15. Weil J, Bell GD, Powell K, et al. Helicobacter pylori infection treated with a tripotassium dicitrato bismuthate and metronidazole combination. Aliment Pharmacol Ther 1990; 4: 651-7.
16. Yousfi MM, El-Zimaity HMT, Al-Assi MT, Cole RA, Genta RM, Graham DY. Metronidazole, omeprazole, and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9: 209-12.
17. Bazzoli F, Zagari RM, Fossi S, et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994; 6: 773-7.
18. Moayyedi P, Sahay P, Tompkins DS, Axon ATR. Efficacy and optimum dose of omeprazole in a new one week triple therapy regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol 1995 (in press).
19. Adamek RJ, Opferkuch W, Wegener M. Modified short-term triple therapy - Ranitidine, clarithromycin, and metronidazole - for cure of Helicobacter pylori infection. Am J Gastroenterol 1995; 90: 168-9 (Letter).
20. Genta RM, Robason GO, Graham DY. Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain. Hum Pathol 1994; 25: 221-6.
21. Hachem CY, Clarridge JE, Reddy R, Flamm R, Evans DG, Graham DY. There are discrepancies between the results of antimicrobial susceptibility testing of Helicobacter pylori using E-test compared to broth microdilution or disk diffusion. Gastroenterology 1995; 108: A106.
22. Nagate T, Numata K, Hanada K, Kondo I. The susceptibility of Campylobacter pylori to antiulcer agents and antibiotics. J Clin Gastroenterol 1990; 12 (Suppl 1): S135-8.
23. Hardy DJ, Hanson CW, Hensey DM, Beyer JM, Fernandes PB. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. J Antimicrob Chemother 1988; 22: 631-6.
24. Xia HX, Daw MA, Beattie S, Keane CT, O'Morain CA. Prevalence of metronidazole-resistant Helicobacter pylori in dyspeptic patients. Ir J Med Sci 1993; 162: 91-4.
25. Graham DY, Klein PD, Opekun AR, et al. In vivo susceptibility of Campylobacter pylori. Am J Gastroenterol 1989; 84: 233-8.
26. Peters DH, Clissold SP. Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 44: 117-64.